ACute Uncomplicated Type b Aortic Dissection: Endovascular Repair vs. Best Medical Therapy

Distal Aortic Dissection Clinical Trial

— ACUTE-B  

Official title:

A Randomized Controlled Comparative Study on Effectiveness of Endovascular Repair Versus Best Medical Therapy for Acute Uncomplicated Type B Aortic Dissection

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02622542
• Other study ID #: CTVS-KC03
• Secondary ID: HSC-MS-15-0937
• Status: Recruiting
• Phase: N/A
• Start date: October 1, 2018
• Est. completion date: June 2026

Study information

• Verified date: January 2022
• Source: The University of Texas Health Science Center, Houston
• Contact: Harleen K Sandhu, MD, MPH
• Phone: 7134865131
• Email: Harleen.K.Sandhu[@]uth.tmc.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to conduct a randomized controlled trial comparing best medical therapy (BMT) alone to BMT with thoracic endovascular aortic repair (BMT+TEVAR) for uncomplicated acute type B aortic dissection.

Description:

Study Design:

This is a prospective, two-arm, parallel-group, single-center, pragmatic, randomized clinical trial.

Population:

The target population comprises all adult patients aged 18 years and older who present with uncomplicated acute type B aortic dissection. The study sample will include 436 subjects of both genders and any race or ethnicity.

Procedures:

Eligible and consented patients will be enrolled into the study if all eligibility criteria are met and will be randomly allocated to one of the two study arms: BMT vs BMT+TEVAR

Study Duration:

The study is expected to accrue patients over the course of 5 years and total follow up per patient for 5 years. Overall duration of the study is anticipated to be about 10 years for completion of all study endpoints.

Endpoints:

• Primary Outcome: To determine all-cause mortality among both study arms.

• Secondary Outcomes: To assess any major morbidity events (rupture, aortic intervention or reintervention, progression to complicated dissection, aneurysm formation, malperfusion resulting in organ failure, and aorta-specific mortality), as will quality of life measures, temporal discounting assessment and outcomes comparison in an observational cohort of patients who decline to be randomized due to a strong treatment preference.

Risks and Benefits:

Since this study involves only usual care and FDA-approved treatments, the investigators do not expect any additional physical risks to patients beyond those associated with usual care. One discernible risk involved in study participants is an unintentional disclosure of sensitive patient health information.

The participants of this study do not stand to benefit directly from taking part. However, the investigators hope that the results obtained from this study would provide useful information that would help delineate a standard and economical management protocol for acute Type B aortic dissection in future.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 436
• Est. completion date: June 2026
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged =18 years, regardless of race or ethnicity;

• Diagnosed with uncomplicated ABAD, i.e., a primary entry tear distal to left subclavian artery with no evidence of malperfusion, end-organ ischemia, rupture, or intractable pain, and onset of symptoms is =30 days prior to enrollment;

• Patient has been stabilized after the acute event with control of pain and blood pressure using =3 intravenous antihypertensive medications;

• Adequate imaging, e.g., CT with contrast (chest + abdomen+ pelvis) is available prior to enrollment; and

• Indicates willingness to comply with the study protocol and is able to provide a written informed consent;

• Meets criteria for inclusion in the National Death Index and Social Security Death Master File.

Exclusion Criteria:

• Diagnosed with Type A aortic dissection;

• Evidence of complicated ABAD;

• Chronic Type B aortic dissection (>6 weeks from onset of symptoms);

• Unable to be randomized and undergo treatment according to protocol within 30 days of symptom onset;

• Diagnosed with traumatic dissection or penetrating ulcer;

• Anatomy is not suitable for TEVAR;

• Previous descending thoracic or abdominal aortic surgery (open or endovascular);

• Unsuitable access sites, including infection at access sites;

• Associated aortic aneurysm (descending aortic diameter =5.0 cm);

• Life expectancy <2 years;

• Unable or unlikely to comply with BMT;

• Unable or refuse to comply with follow-up;

• Intend to participate in another trial within 3 months of enrollment;

• Pregnant or breast-feeding;

• Vasculitis or known genetic connective tissue disorder (Marfan's syndrome or Ehlers-Danlos syndrome)

• Active systemic infection;

• Chronic kidney disease stage 3-5 (estimated glomerular filtration rate <60 mL/min/1.73m2);

• Cerebral vascular accident within past 3 months; or

• Clinically significant gastrointestinal bleeding, major surgery, myocardial infarction, or untreated coagulopathy within past 6 weeks.

Related Conditions & MeSH terms

• Acute Type B Aortic Dissection (Uncomplicated)
• Aneurysm, Dissecting
• Dissection, Aortic Acute
• Distal Aortic Dissection

Intervention

Device:
• BMT+TEVAR
These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)

Other:
• BMT
Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.

Locations

Country	Name	City	State
United States	Department of Cardiothoracic and Vascular Surgery and Memorial Hermann Heart and Vascular Institute - Texas Medical Center	Houston	Texas
United States	Department of Cardiothoracic and Vascular Surgery; Memorial Hermann Hospital Southeast	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
The University of Texas Health Science Center, Houston

Country where clinical trial is conducted

United States, 

References & Publications (3)

Afifi RO, Sandhu HK, Leake SS, Boutrous ML, Kumar V 3rd, Azizzadeh A, Charlton-Ouw KM, Saqib NU, Nguyen TC, Miller CC 3rd, Safi HJ, Estrera AL. Outcomes of Patients With Acute Type B (DeBakey III) Aortic Dissection: A 13-Year, Single-Center Experience. Circulation. 2015 Aug 25;132(8):748-54. doi: 10.1161/CIRCULATIONAHA.115.015302. — View Citation

Nienaber CA, Kische S, Rousseau H, Eggebrecht H, Rehders TC, Kundt G, Glass A, Scheinert D, Czerny M, Kleinfeldt T, Zipfel B, Labrousse L, Fattori R, Ince H; INSTEAD-XL trial. Endovascular repair of type B aortic dissection: long-term results of the randomized investigation of stent grafts in aortic dissection trial. Circ Cardiovasc Interv. 2013 Aug;6(4):407-16. doi: 10.1161/CIRCINTERVENTIONS.113.000463. Epub 2013 Aug 6. — View Citation

Nienaber CA, Rousseau H, Eggebrecht H, Kische S, Fattori R, Rehders TC, Kundt G, Scheinert D, Czerny M, Kleinfeldt T, Zipfel B, Labrousse L, Ince H; INSTEAD Trial. Randomized comparison of strategies for type B aortic dissection: the INvestigation of STEnt Grafts in Aortic Dissection (INSTEAD) trial. Circulation. 2009 Dec 22;120(25):2519-28. doi: 10.1161/CIRCULATIONAHA.109.886408. Epub 2009 Dec 7. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	All-cause mortality	Participants would be followed for a period of 5 years following initial presentation	5 years
Secondary	Any major morbidity events	Participants would be followed for a period of 5 years following initial presentation to record any major events (rupture, aortic intervention or reintervention, progression to complicated dissection, aneurysm formation, malperfusion resulting in organ failure, and aorta-specific mortality)	5 years
Secondary	Change in Quality of Life assessment	Participants would be followed for a period of 5 years following initial presentation to assess the change in their quality of life as compared to baseline or prior to disease onset by using Aortic Disease Quality of Life (ADQoL) instrument and the validated general health related quality of life instrument called Short Form -12 (SF-12). The ADQoL is an instrument that measures the quality of life in 5 major domains - physical limitations, social limitations, general health perceptions, emotional limitations, and aortic-disease specific limitations. Lower scores on individual subscales and overall are deemed to be poor quality of life and higher scores indicate good quality of life. the SF-12 is also designed to assess general health related quality of life and is also scored and assessed similarly, i.e, higher scores indicate good general health related quality of life and measures health perception, physical, emotional, and social limitations.	5 years